NATURE’S FIRST RESPONDER™

OF OUR COMPREHENSIVE ONCOLOGY PIPELINE

haNK® and t-haNKTM
THE NANT CANCER VACCINE
Harnessing the Power of Our Immune System

nantkwest

NATURE’S FIRST RESPONDER™

OF OUR COMPREHENSIVE ONCOLOGY PIPELINE
haNK® and t-haNKTM
THE NANT CANCER VACCINE
Harnessing the Power of Our Immune System

Pipeline

NK Pipeline
N-803 is an IL-15RαFc Superagonist, a proprietary therapeutic cytokine designed to induce expansion of native NK and CD8+ T-cells without concurrent stimulation of T-regulatory cells; Aldoxorubicin (Aldox) is a proprietary albumin-bound doxorubicin complex that is designed to preferentially accumulate in a tumor’s low pH environment. Both agents are in late-stage clinical development by our affiliate, ImmunityBio, which has exclusive, worldwide rights to the agents. Avelumab is an FDA approved checkpoint inhibitor marketed by Pfizer.

* Program owned by NantKwest and subject to Joint Development Agreement with ImmunityBio
† Program owned by ImmunityBio and subject to Joint Development Agreement with NK ‡ QUILT number not yet designated

To learn more about the Nant Cancer Vaccine

To learn more about our clinical trials